Physician profile
Richard A Hoffman
NPI 1568561280
$7,231.74
in general payments reported to CMS, 2019-2025
31 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $73.93 · 2021: $330 · 2022: $1,774 · 2023: $1,523 · 2024: $1,538 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,065 · Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,065.29 |
| Food and Beverage | $1,622.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $4,086.12 | 2022-2025 | (8269) Dreamstation Cpap, Dreamstation Cpap |
| Harmony Biosciences LLC | $491.85 | 2020-2024 | Wakix |
| Astrazeneca Pharmaceuticals LP | $369.43 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $350.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $341.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $243.84 | 2019-2022 | |
| Amgen INC. | $168.34 | 2022-2025 | Tezspire |
| Axsome Therapeutics, INC. | $151.62 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $147.74 | 2024-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.37 | 2019-2024 | Ofev |
| Insmed, INC. | $89.95 | 2019-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $71.15 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $70.85 | 2019-2023 | Yupelri |
| Pfizer INC. | $65.81 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $56.84 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $51.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.88 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $33.87 | 2019 | |
| Genentech USA, INC. | $27.39 | 2022 | |
| Novo Nordisk INC | $25.92 | 2024 | Wegovy |
| Arbor Pharmaceuticals, INC. | $25.25 | 2021 | |
| Inspire Medical Systems, INC. | $24.71 | 2025 | Inspire |
| Lilly USA, LLC | $23.97 | 2025 | Zepbound |
| Electromed, INC. | $21.97 | 2023 | Smartvest |
| Paratek Pharmaceuticals, INC. | $21.55 | 2023 | Nuzyra |
| 3b Medical, INC. | $20.84 | 2025 | Luna |
| Mallinckrodt Hospital Products INC. | $20.75 | 2024 | Acthar |
| Pulmonx Corporation | $20.33 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $15.22 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $15.17 | 2021 | |
| Merck Sharp & Dohme LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.